ProCE Banner Activity

CADENZA: Patient-Reported and Quality-of-Life Outcomes From Phase III Study of Sutimlimab vs Placebo in Patients With Cold Agglutinin Disease

Slideset Download
Conference Coverage

In patients with CAD without a recent transfusion history, the classical complement pathway inhibitor sutimlimab was associated with improvements in fatigue and quality of life that were maintained for more than 1 year.

Released: December 16, 2022

Expiration: December 15, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen